Sonnet BioTherapeutics (SONN)
(Delayed Data from NSDQ)
$2.65 USD
-0.16 (-5.69%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $2.71 +0.06 (2.26%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Sonnet BioTherapeutics Holdings, Inc.'s return on equity, or ROE, is -777.92% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.42%. While this shows that SONN has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
SONN 2.65 -0.16(-5.69%)
Will SONN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SONN based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for SONN
Sonnet BioTherapeutics (SONN) Expands Cancer Drug Study
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with ...
Sonnet BioTherapeutics expands clinical evaluation of SON-1010 dose escalation
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session